Pharmaids Pharmaceuticals share news, announcements and annual reports
BSE: 524572Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹28.42.
30 Oct: open ₹28.00, high ₹28.89, low ₹27.50
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹98 Cr2,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.05
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −8.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹6.70 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −21.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.44
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,285
Pharmaids Pharmaceuticals share news and announcements
617 announcements, routine notices left out, newest first. Page 9 of 13.
Jan 2020
10 Jan · Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Nov 2019
27 Nov · Announcement under Regulation 30 (LODR)-Allotment
13 Nov · Unaudited Quarter & Half Year Ended 30Th Sept'2019
Oct 2019
17 Oct · Board meeting
Meeting on 13 Nov 2019: quarterly results16 Oct · Regulation 40(9) For 30Th Sept'19
16 Oct · Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulation,2015 For Half Year Ended September 30Th,2019.
14 Oct · Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 014 Oct · Shareholding for the Period Ended September 30, 2019
Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click ....5 Oct · Board meeting
1 Oct · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....
Sep 2019
Aug 2019
27 Aug · Board meeting
2 Aug · Board meeting
Meeting on 13 Aug 2019: quarterly results
Jul 2019
17 Jul · Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 017 Jul · Shareholding for the Period Ended June 30, 2019
Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click ....10 Jul · Corporate Insolvency Resolution Process (CIRP)-Public Announcement
Jun 2019
27 Jun · Compliance Under Regulation 23(9)Of SEBI Regualtion, 2015
18 Jun · Result Financial Statement 31.03.2019
May 2019
15 May · Board meeting
Meeting on 27 May 2019: quarterly results and audited results13 May · Outcome Of The NCLT Convened Meeting
11 May · Regulation 30 - Proceedings Of The NCLT Convened Meeting Of The Equity Shareholders Reg., Held On May 11, 2019
Apr 2019
29 Apr · Certificate Under Regulation 40(9) Of SEBI
29 Apr · APRIL 2019
20 Apr · Shareholding for the Period Ended March 31, 2019
Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click ....20 Apr · Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 08 Apr · Board meeting
8 Apr · Board meeting
5 Apr · Board meeting
2 Apr · Board meeting
Meeting on 5 Apr 2019: amalgamation